BioSpace News Archive

Ageism, or discrimination against an individual based on their age, is a common barrier many older individuals face in the workplace. Fortunately, there are steps that can be taken to mitigate this discrimination.

Sanofi and Regeneron’s Dupixent (dupilumab) met its primary and all secondary endpoints in the Phase III BOREAS trial, significantly reducing severe exacerbations in COPD.

Wednesday, the FDA approved Cidara Therapeutics and Melinta Therapeutics’ Rezzayo (rezafungin) injection to treat candidemia and invasive candidiasis.

Novo Nordisk and Dewpoint Therapeutics have inked a deal to use the latter’s biomolecular condensates discovery platform to treat insulin resistance and diabetic complications.

Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), (“Kiora” or the “Company”) today is providing a business update and reporting financial results for the year ended December 31, 2022.

The FDA’s Peripheral and Central Nervous System Drugs Advisory Committee voted 9-0 that tofersen’s effect on neurofilament light chain (NfL) could be a reasonable predictor of clinical benefit.

Valneva SE a specialty vaccine company, reported its consolidated financial results for the year ending December 31, 20224 and provided corporate updates.

Sosei Group Corporation announces the election of Ms. Eiko Tomita to the Board of Directors as an Independent External Director, and the promotion of Ms. Candelle Chong to Executive Vice President and Chief of Staff at the Company’s 33rd Annual Shareholders’ Meeting and a subsequent Board of Directors meeting, held in Tokyo.

PureTech Health plc and Royalty Pharma announced that Royalty Pharma has acquired an interest in PureTech’s royalty in Karuna Therapeutics’ KarXT for up to $500 million, with $100 million in cash up front and up to $400 million in additional payments contingent on the achievement of certain regulatory and commercial milestones.

ONO PHARMA USA, INC., announced that its candidate, tirabrutinib, a Bruton’s tyrosine kinase inhibitor, was granted Orphan Drug Designation on March 21, 2023 by the U.S. Food and Drug Administration for the treatment of patients with primary central nervous system lymphoma.